<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05018975</url>
  </required_header>
  <id_info>
    <org_study_id>1111111</org_study_id>
    <nct_id>NCT05018975</nct_id>
  </id_info>
  <brief_title>Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection</brief_title>
  <acronym>IST</acronym>
  <official_title>Repurposing Tazemetostat for the Treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 Patient</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ciprian Gheorghe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Loma Linda University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat&#xD;
      for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release&#xD;
      Syndrome (SCRS) in COVID-19 patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that tazemetostat will mitigate the hyperinflammatory effects&#xD;
      of COVID-19 infection, prevent respiratory deterioration, and reduce requirements of invasive&#xD;
      ventilation. This will be conducted as a Phase II open label study. After being informed&#xD;
      about the study and potential risks, all patients giving written informed consent will&#xD;
      undergo randomization to receive 800 mg tazemetostat BID for 15 days in addition to standard&#xD;
      of care treatment. The duration of the interventional part of the study will last 15 days,&#xD;
      additionally the patients will be evaluated at 30 and 90 days for overall clinical status and&#xD;
      sequelae. The study will be conducted at a single site (Loma Linda University Medical&#xD;
      Center).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 22, 2021</start_date>
  <completion_date type="Anticipated">September 21, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 21, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluating the ability of tazemetostat to reduce need for mechanical ventilation and ECMO in severe COVID-19 patients</measure>
    <time_frame>15 days after treatment</time_frame>
    <description>15 days after treatment initiation investigators will assess the composite endpoint of requirement for mechanical ventilation or ECMO</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the effect of tazemetostat treatment of the course of COVID-19 disease</measure>
    <time_frame>From date of randomization until the date discharge or in-hospital death from any cause, whichever came first, assessed up to 1 year</time_frame>
    <description>To characterize this outcome measure, investigators will assess the length of stay in the hospital.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Evaluating the change in inflammatory status in response to tazemetostat</measure>
    <time_frame>From date of randomization up to 15 days</time_frame>
    <description>CRP levels, ESR, IL-6, D-dimer, lactate dehydrogenase, neutrophil-to-lymphocyte ratio, cardiac troponin, renal biomarkers, lymphocytes and platelet count</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">82</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>Cytokine Release Syndrome</condition>
  <arm_group>
    <arm_group_label>Tazemetostat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive tazemetostat 800mg BID for 15 days in addition to standard of care treatment. The duration of the interventional part of the study will last 15 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects receiving standard of care treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat 800mg BID PO dosing for 15 days</description>
    <arm_group_label>Tazemetostat</arm_group_label>
    <other_name>Tazemetostat oral tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of signed and dated informed consent form&#xD;
&#xD;
          -  Stated willingness to comply with all study procedures and availability for the&#xD;
             duration of the study.&#xD;
&#xD;
          -  Male or female, aged 18-85&#xD;
&#xD;
          -  Diagnosed with q-PCR confirmed infection with SARS-Cov-2 virus and admitted to the&#xD;
             hospital.&#xD;
&#xD;
          -  Receiving non-invasive respiratory support through a nasal cannula or a face mask.&#xD;
&#xD;
          -  Ability to take oral medication and be willing to adhere to the tazemetostat regimen.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to take PO medication.&#xD;
&#xD;
          -  Need for intubation or ECMO.&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Known allergic reactions to tazemetostat.&#xD;
&#xD;
          -  Active malignancy (not in remission).&#xD;
&#xD;
          -  Treatment with another investigational drug.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ciprian P Gheorghe, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ashra Tugung, BSc</last_name>
    <phone>9096515580</phone>
    <email>atugung@llu.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nikia Gray-Hutto, RN, CCRP</last_name>
    <phone>9096515841</phone>
    <email>nhutto@llu.edu</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 19, 2021</study_first_submitted>
  <study_first_submitted_qc>August 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 24, 2021</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Loma Linda University</investigator_affiliation>
    <investigator_full_name>Ciprian Gheorghe</investigator_full_name>
    <investigator_title>Principal Investigator, Assistant Professor, Gynecology &amp; Obstetrics and Basic Sciences</investigator_title>
  </responsible_party>
  <keyword>Systemic Cytokine Release Syndrome Due to SARS-CoV-2 Disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

